Vanguard Capital Management’s Monopar Therapeutics MNPR Stock Holding History
Bought
Maintained
Sold
Other funds holding MNPR
SVCM
SL
Vanguard Capital Management's MNPR Position: Q3 2026 in Review
Vanguard Capital Management increased its Monopar Therapeutics (MNPR) stake by 3.9% in Q3 2026, buying an estimated $884K and bringing the position to 217,958 shares worth $17.4M. The position accounts for ﹤0.01% of the portfolio, ranked #2467.
Vanguard Capital Management first reported a position in MNPR in Q1 2026 and has held it in 3 quarters since. The position peaked at $19.4M in Q2 2026. 106 funds tracked by Wall St. Rank hold MNPR as of Q3 2026.
- Vanguard Capital Management held 217,958 shares of Monopar Therapeutics worth $17.4M as of Q3 2026.
- Vanguard Capital Management bought 8,247 Monopar Therapeutics shares in Q3 2026, an estimated $884K.
- Monopar Therapeutics made up ﹤0.01% of Vanguard Capital Management's portfolio in Q3 2026, its #2467 holding.
- Vanguard Capital Management first reported a position in Monopar Therapeutics in Q1 2026 and has held it in 3 quarters since.
- Vanguard Capital Management's Monopar Therapeutics position peaked at $19.4M in Q2 2026.
- 106 funds tracked by Wall St. Rank held Monopar Therapeutics as of Q3 2026.
Based on Vanguard Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.